Segment & Geographic Data
Quant-Grade Normalized (live API)
API & CSV Delivery
Mirum Pharmaceuticals Inc's Business Segments
Mirum Pharmaceuticals Inc's reported revenue by business segment and by geographic region, quarterly and annual, normalized against the consolidated income statement. Free below: the top 3 rows per table, this quarter and this fiscal year. Subscriber access adds the full segment history and operating income by segment.
Segment Data As of Q1 FY2026
Reportable Segments
-
Largest Segment
-
Total Revenue
$ 160
Regions Reported
-
Revenue by Product & Service Category - Q1 FY2026
- Product100%
- Livmarli71.2%
- Bile Acid Medicines28.8%
Revenue by Product & Service Category - Q1 FY2026
| Category | Revenue (Millions) | % of Total |
|---|---|---|
| Product | $ 160 | 100% |
| Livmarli | $ 114 | 71.2% |
| Bile Acid Medicines | $ 46 | 28.8% |
Product and service categories are a supplemental disclosure and are not required to sum to consolidated revenue or to the reportable segments above.
Description of Mirum Pharmaceuticals Inc's Business Segments
Mirum Pharmaceuticals Inc. is a biopharmaceutical company dedicated to developing and delivering innovative therapies for patients with rare liver diseases. The company focuses on diseases that lack effective treatment options and strives to make a significant impact on patients' lives.
Mirum Pharmaceuticals is headquartered in Foster City, California, United States. Founded in 2018, the company has quickly emerged as a leading player in the field of liver diseases. Their team consists of experienced professionals with expertise in drug development, clinical research, and regulatory processes.
The company's primary area of research and development is rare cholestatic liver diseases, which affect the flow of bile from the liver. These diseases include Alagille syndrome, progressive familial intrahepatic cholestasis (PFIC), and bile acid synthesis disorders (BASD). Patients with these conditions often experience severe itching (pruritus), liver damage, and a reduced quality of life.
Mirum Pharmaceuticals is dedicated to developing targeted therapies that address the underlying causes of these diseases. Their lead product candidate, maralixibat, is an oral inhibitor of the apical sodium-dependent bile acid transporter (ASBT). By inhibiting ASBT, maralixibat reduces the reabsorption of bile acids, thereby reducing their toxic accumulation in the liver and improving symptoms of cholestatic liver diseases.
The company has conducted several clinical trials to evaluate the safety and efficacy of maralixibat. These trials have shown promising results, with improvements in laboratory markers of liver function, reduction in pruritus, and improved overall quality of life for patients. Mirum Pharmaceuticals is actively working to bring maralixibat to market and secure regulatory approvals to make it available to patients worldwide.
Aside from maralixibat, Mirum Pharmaceuticals also has an extensive pipeline of potential therapies for other rare liver diseases. They are actively exploring novel treatment approaches, including gene therapies and small molecules targeted at specific genetic mutations responsible for various liver diseases.
Mirum Pharmaceuticals is committed to patient-centric research and development. They collaborate closely with patient advocacy groups, healthcare providers, and regulatory authorities to ensure that their therapies meet the needs of patients and families affected by rare liver diseases. The company recognizes the critical unmet medical need in this space and aims to address it through their groundbreaking research and development efforts.
In summary, Mirum Pharmaceuticals Inc. is an innovative biopharmaceutical company that focuses on developing targeted therapies for rare liver diseases. Their lead product candidate, maralixibat, has shown promising results in treating cholestatic liver diseases and improving patients' lives. With a strong pipeline of potential therapies and a patient-centric approach, Mirum Pharmaceuticals is poised to make a significant impact in the field of liver disease treatment.
Mirum Pharmaceuticals is headquartered in Foster City, California, United States. Founded in 2018, the company has quickly emerged as a leading player in the field of liver diseases. Their team consists of experienced professionals with expertise in drug development, clinical research, and regulatory processes.
The company's primary area of research and development is rare cholestatic liver diseases, which affect the flow of bile from the liver. These diseases include Alagille syndrome, progressive familial intrahepatic cholestasis (PFIC), and bile acid synthesis disorders (BASD). Patients with these conditions often experience severe itching (pruritus), liver damage, and a reduced quality of life.
Mirum Pharmaceuticals is dedicated to developing targeted therapies that address the underlying causes of these diseases. Their lead product candidate, maralixibat, is an oral inhibitor of the apical sodium-dependent bile acid transporter (ASBT). By inhibiting ASBT, maralixibat reduces the reabsorption of bile acids, thereby reducing their toxic accumulation in the liver and improving symptoms of cholestatic liver diseases.
The company has conducted several clinical trials to evaluate the safety and efficacy of maralixibat. These trials have shown promising results, with improvements in laboratory markers of liver function, reduction in pruritus, and improved overall quality of life for patients. Mirum Pharmaceuticals is actively working to bring maralixibat to market and secure regulatory approvals to make it available to patients worldwide.
Aside from maralixibat, Mirum Pharmaceuticals also has an extensive pipeline of potential therapies for other rare liver diseases. They are actively exploring novel treatment approaches, including gene therapies and small molecules targeted at specific genetic mutations responsible for various liver diseases.
Mirum Pharmaceuticals is committed to patient-centric research and development. They collaborate closely with patient advocacy groups, healthcare providers, and regulatory authorities to ensure that their therapies meet the needs of patients and families affected by rare liver diseases. The company recognizes the critical unmet medical need in this space and aims to address it through their groundbreaking research and development efforts.
In summary, Mirum Pharmaceuticals Inc. is an innovative biopharmaceutical company that focuses on developing targeted therapies for rare liver diseases. Their lead product candidate, maralixibat, has shown promising results in treating cholestatic liver diseases and improving patients' lives. With a strong pipeline of potential therapies and a patient-centric approach, Mirum Pharmaceuticals is poised to make a significant impact in the field of liver disease treatment.
Mirum Pharmaceuticals, Inc. is a biotechnology company focused on developing innovative medicines for the treatment of rare liver diseases. The company is dedicated to creating therapies that can significantly improve the quality of life for patients with these conditions. Below is an extensive description of the segments, products, and services that Mirum Pharmaceuticals offers, reflecting its core focus areas and therapeutic advancements.
Segments
1. Rare Liver Diseases
- Mirum specializes in addressing unmet medical needs in the field of rare liver diseases. This segment includes an array of conditions that significantly impact liver function and patient quality of life.
2. Research and Development (R&D)
- A pivotal segment of Mirums operations is its commitment to R&D. The company invests in clinical trials and studies aimed at discovering and developing new therapeutic options for patients suffering from liver-related disorders.
3. Commercialization
- Once products reach market readiness, Mirum engages in commercialization efforts to ensure that therapies are accessible to healthcare providers and patients. This includes marketing strategies, physician education initiatives, and patient access programs.
Products
1. Maralixibat
- Indication: Maralixibat is Mirums lead product candidate, primarily developed for the treatment of cholestatic liver diseases, including Alagille syndrome and biliary atresia.
- Mechanism of Action: It is an oral apical sodium-dependent bile acid transporter (ASBT) inhibitor. By blocking the reabsorption of bile acids in the intestine, it promotes their excretion, which may alleviate symptoms and improve liver function.
- Clinical Development: Maralixibat has undergone various stages of clinical trials and has shown promise in improving liver-related outcomes in patients with cholestatic diseases.
2. Additional Pipeline Candidates
- Mirum continues to expand its product pipeline with other candidates targeted at rare liver disease indications. Specific details about these candidates may vary, focusing on novel therapeutic approaches.
Services
1. Patient Support Programs
- Mirum provides comprehensive patient support services designed to assist patients in navigating their treatment journey. These programs may include medication management, counseling, and connections to healthcare professionals.
2. Healthcare Provider Engagement
- The company actively engages with healthcare providers through educational initiatives, workshops, and resources to empower them with knowledge about rare liver diseases and the potential efficacy of Mirums products.
3. Clinical Trial Participation
- As part of its R&D efforts, Mirum facilitates and manages clinical trials, allowing patients to participate in studies that test new therapies. This can provide patients with access to cutting-edge treatments while contributing to the development of new medications.
4. Advocacy and Awareness
- Mirum is involved in advocacy efforts to raise awareness about rare liver diseases. This includes partnerships with patient advocacy groups and participation in awareness campaigns to educate the public and increase understanding of these conditions.
5. Regulatory Affairs
- The company actively engages with regulatory agencies to navigate the complexities of gaining approvals for its therapies. This includes preparing and submitting regulatory documents and responding to queries throughout the drug development process.
Conclusion
Mirum Pharmaceuticals, Inc. embodies a focused approach in the biotechnology sector with an emphasis on rare liver diseases. Through innovative product development like maralixibat and comprehensive support services for both patients and healthcare providers, the company is positioned to address critical unmet needs in this specialized field. The ongoing commitment to R&D and patient engagement highlights Mirums dedication to improving outcomes for those suffering from challenging liver conditions.
Segments
1. Rare Liver Diseases
- Mirum specializes in addressing unmet medical needs in the field of rare liver diseases. This segment includes an array of conditions that significantly impact liver function and patient quality of life.
2. Research and Development (R&D)
- A pivotal segment of Mirums operations is its commitment to R&D. The company invests in clinical trials and studies aimed at discovering and developing new therapeutic options for patients suffering from liver-related disorders.
3. Commercialization
- Once products reach market readiness, Mirum engages in commercialization efforts to ensure that therapies are accessible to healthcare providers and patients. This includes marketing strategies, physician education initiatives, and patient access programs.
Products
1. Maralixibat
- Indication: Maralixibat is Mirums lead product candidate, primarily developed for the treatment of cholestatic liver diseases, including Alagille syndrome and biliary atresia.
- Mechanism of Action: It is an oral apical sodium-dependent bile acid transporter (ASBT) inhibitor. By blocking the reabsorption of bile acids in the intestine, it promotes their excretion, which may alleviate symptoms and improve liver function.
- Clinical Development: Maralixibat has undergone various stages of clinical trials and has shown promise in improving liver-related outcomes in patients with cholestatic diseases.
2. Additional Pipeline Candidates
- Mirum continues to expand its product pipeline with other candidates targeted at rare liver disease indications. Specific details about these candidates may vary, focusing on novel therapeutic approaches.
Services
1. Patient Support Programs
- Mirum provides comprehensive patient support services designed to assist patients in navigating their treatment journey. These programs may include medication management, counseling, and connections to healthcare professionals.
2. Healthcare Provider Engagement
- The company actively engages with healthcare providers through educational initiatives, workshops, and resources to empower them with knowledge about rare liver diseases and the potential efficacy of Mirums products.
3. Clinical Trial Participation
- As part of its R&D efforts, Mirum facilitates and manages clinical trials, allowing patients to participate in studies that test new therapies. This can provide patients with access to cutting-edge treatments while contributing to the development of new medications.
4. Advocacy and Awareness
- Mirum is involved in advocacy efforts to raise awareness about rare liver diseases. This includes partnerships with patient advocacy groups and participation in awareness campaigns to educate the public and increase understanding of these conditions.
5. Regulatory Affairs
- The company actively engages with regulatory agencies to navigate the complexities of gaining approvals for its therapies. This includes preparing and submitting regulatory documents and responding to queries throughout the drug development process.
Conclusion
Mirum Pharmaceuticals, Inc. embodies a focused approach in the biotechnology sector with an emphasis on rare liver diseases. Through innovative product development like maralixibat and comprehensive support services for both patients and healthcare providers, the company is positioned to address critical unmet needs in this specialized field. The ongoing commitment to R&D and patient engagement highlights Mirums dedication to improving outcomes for those suffering from challenging liver conditions.